Roth MKM analysts named 16 software (IGPT), (XSW), (BATS:IGV) stocks to look out for. Software (IGV) has been “quietly starting to break out at
Bullish
Bitcoin Price Analysis: Increased Futures Activity and Open Interest Hint at Bullish Momentum
Bitcoin futures activity surges, with open interest hitting $34.63 billion across major exchanges, hinting at potential bullish momentum for the largest cryptocurrency.
Bitcoin is stuck in a tight range. Are we still on track for a bullish breakout next year?
The MN Consultancy CIO and Founder stated that Bitcoin’s price has been stuck in a tight price range and explained different indicators explaining the
The stock market is overvalued, but that’s no reason to turn bearish, analyst says
“Stocks can remain at rich valuations as long as a ‘fear’ catalyst doesn’t arise from the usual suspects: interest rates, employment or inflation.” …
NTT: Bullish On Capital Return Improvement And Potential REIT Listing
NTT Corporation’s potential data center REIT listing could put a bigger spotlight on the telecom’s data center assets. Read more on NTT’s capital returns
Trump Media’s Stock Surges as Investors Grow More Bullish on His Chance of Winning U.S. Presidential Election
Trump Media investors have rallied behind the stock as betting sites have increased their odds that Trump will win the U.S. presidential election.
Buy Rating Affirmed for Zevra Therapeutics Based on Strong NPV and Future Market Potential
William Blair analyst Sami Corwin has maintained their bullish stance on ZVRA stock, giving a Buy rating on October 7. Sami Corwin has given
3 Stocks Poised for Massive Short Squeezes in the Next 4-6 Weeks
Short-term traders may consider the $47.50 price a target for Fox Corp. shares over the next 4-6 weeks, a 15% rally from current prices.
Beyond The Numbers: 14 Analysts Discuss Marvell Tech Stock
The 12-month price targets, analyzed by analysts, offer insights with an average target of $95.57, a high estimate of $120.00, and a low estimate
Amgen’s stock falls as analyst warns that hype around obesity drug is baked in
Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.